Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting

- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.

BenzingaJun 4 08:27 ET

Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma -BERKELEY HEIGHTS, N.J., June 0

BenzingaJun 3 08:38 ET

Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Yahoo FinanceMay 15 05:01 ET

10-Q: Quarterly report

SEC announcementMay 14 17:16 ET · Announcements

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative

GlobeNewswireMay 8 09:15 ET

Express News | Cyclacel Pharmaceuticals Inc Files for Resale of up to 15.2 Mln Shares by the Selling Stockholders - SEC Filing

ReutersMay 6 17:28 ET